Work

Tracking Down Response and Resistance to TRK Inhibitors

Year: 2016

Type: article

Abstract: Summary: Two recent studies validate the LMNA–NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA–NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker–based clinical trials across cancer subtypes.Cancer Discov; 6(1); 14–6. ©2016 AACR. See related article by Russo et al., p. 36.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-15-1352

Authors: Ross A. Okimoto, Trever G. Bivona

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute